NM_002485.5(NBN):c.2216T>C (p.Leu739Pro) AND Microcephaly, normal intelligence and immunodeficiency

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Aug 2, 2021
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV001872072.6

Allele description [Variation Report for NM_002485.5(NBN):c.2216T>C (p.Leu739Pro)]

NM_002485.5(NBN):c.2216T>C (p.Leu739Pro)

Gene:

NBN:nibrin [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

8q21.3

Genomic location:

Preferred name:

NM_002485.5(NBN):c.2216T>C (p.Leu739Pro)

HGVS:

NC_000008.11:g.89937044A>G
NG_008860.1:g.52628T>C
NM_001024688.3:c.1970T>C
NM_002485.5:c.2216T>CMANE SELECT
NP_001019859.1:p.Leu657Pro
NP_002476.2:p.Leu739Pro
LRG_158t1:c.2216T>C
LRG_158:g.52628T>C
NC_000008.10:g.90949272A>G

Protein change:

L657P

Links:

dbSNP: rs2130739195

NCBI 1000 Genomes Browser:

rs2130739195

Molecular consequence:

NM_001024688.3:c.1970T>C - missense variant - [Sequence Ontology: SO:0001583]
NM_002485.5:c.2216T>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:: Microcephaly, normal intelligence and immunodeficiency (NBS)
Synonyms:: IMMUNODEFICIENCY, MICROCEPHALY, AND CHROMOSOMAL INSTABILITY; SEEMANOVA SYNDROME II; Nijmegen breakage syndrome; See all synonyms [MedGen]
Identifiers:: MONDO: MONDO:0009623; MedGen: C0398791; Orphanet: 647; OMIM: 251260

Recent activity

Clear Turn Off Turn On

BB330140 RIKEN full-length enriched, 6 days neonate medulla oblongata Mus muscul...
BB330140 RIKEN full-length enriched, 6 days neonate medulla oblongata Mus musculus cDNA clone B730007L04 3', mRNA sequence
gi|9038903|gnl|dbEST|5216595|dbj|BB 0.1|

Nucleotide
RecName: Full=Alpha-(1,6)-fucosyltransferase; Short=Alpha1-6FucT; AltName: Full=...
RecName: Full=Alpha-(1,6)-fucosyltransferase; Short=Alpha1-6FucT; AltName: Full=Fucosyltransferase 8; AltName: Full=GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha1,6-fucosyltransferase; AltName: Full=GDP-fucose--glycoprotein fucosyltransferase; AltName: Full=Glycoprotein 6-alpha-L-fucosyltransferase
gi|52000676|sp|Q6EV77.1|FUT8_PANTR

Protein
Profile neighbors for GEO Profiles (Select 132553112) (199)
GEO Profiles
Related DataSets for GEO Profiles (Select 132575043) (1)
GEO DataSets
MicroRNA-135b overexpression effect on prostate cancer cell line: time course
MicroRNA-135b overexpression effect on prostate cancer cell line: time course
Accession: GDS6100

GEO DataSets

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV002313914	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Uncertain significance (Aug 2, 2021)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV002313914

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Uncertain significance
(Aug 2, 2021)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]

PMID:: 28492532
PMCID:: PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV002313914.3

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (1)

Description

In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 1171798). This variant has not been reported in the literature in individuals affected with NBN-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces leucine with proline at codon 739 of the NBN protein (p.Leu739Pro). The leucine residue is moderately conserved and there is a moderate physicochemical difference between leucine and proline.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Oct 26, 2024

ClinVar

Relating variation to medicine